BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer
Retrieved on:
Thursday, June 17, 2021
Oncology, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Drugs, Cancer treatments, Clinical medicine, Orphan drugs, Monoclonal antibodies, Cancer immunotherapy, Breakthrough therapy, Pembrolizumab, Tislelizumab, Humanized antibody, PD-1 and PD-L1 inhibitors, Ociperlimab (BGB-A1217), Tislelizumab, the Tislelizumab Clinical Program, BeiGene, OCIPERLIMAB (BGB-A1217), TISLELIZUMAB, THE TISLELIZUMAB CLINICAL PROGRAM, BEIGENE
This marks the initiation of the first Phase 3 clinical trial in the planned global pivotal program for ociperlimab.
Key Points:
- This marks the initiation of the first Phase 3 clinical trial in the planned global pivotal program for ociperlimab.
- Ociperlimab is a potent anti-TIGIT antibody with intact Fc function, which we believe to be critical for the anti-tumor activities of TIGIT antibodies.
- Patients will be randomized to receive ociperlimab and tislelizumab combination treatment, pembrolizumab, or tislelizumab alone.
- Ociperlimab (BGB-A1217) is an investigational humanized IgG 1 monoclonal antibody discovered and being developed globally by BeiGene.